gvtcx

NHS National Framework for Transition products commencing 1 October 2024

NHS England Published 17 Oct 2024 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£131,960,000
Statuscomplete
Category (CPV) 33600000
Deadline29 Jul 2024
Procedureopen
OCIDocds-h6vhtk-0472c3

Awards (24)

This procurement was awarded to 12 suppliers. Values shown are per-award; the notice total is £131,960,000.

SupplierValueDateStatus
Accord-UK Ltd shared £16,224,000 29 Sept 2024 active
Accord-UK Ltd shared · · active
Amarox Limited shared £16,224,000 29 Sept 2024 active
Amarox Limited shared · · active
Celix Pharma Ltd. shared £16,224,000 29 Sept 2024 active
Celix Pharma Ltd. shared · · active
Dr.Reddy's Laboratories (UK) Limited shared £16,224,000 29 Sept 2024 active
Dr.Reddy's Laboratories (UK) Limited shared · · active
Gilead Sciences Limited shared £16,224,000 29 Sept 2024 active
Gilead Sciences Limited shared · · active
Glenmark Pharmaceuticals Europe Limited shared £16,224,000 29 Sept 2024 active
Glenmark Pharmaceuticals Europe Limited shared · · active
Mercury Pharmaceuticals Limited shared £16,224,000 29 Sept 2024 active
Mercury Pharmaceuticals Limited shared · · active
Seacross Pharmaceuticals Ltd shared £16,224,000 29 Sept 2024 active
Seacross Pharmaceuticals Ltd shared · · active
Teva UK Limited shared £16,224,000 29 Sept 2024 active
Teva UK Limited shared · · active
Thornton and Ross Ltd shared £16,224,000 29 Sept 2024 active
Thornton and Ross Ltd shared · · active
Tillomed Laboratories ltd shared £16,224,000 29 Sept 2024 active
Tillomed Laboratories ltd shared · · active
Zentiva Pharma UK Ltd shared £16,224,000 29 Sept 2024 active
Zentiva Pharma UK Ltd shared · · active

description

Project title: NHS National Framework for Transition products commencing 1 October 2024<br/>Offer reference number: CM/TNS/24/5712<br/>Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.<br/>Potential periods of call-offs under the framework agreement:<br/> <br/>CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets<br/>Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) <br/><br/>CM/TNS/24/5712/02 - Imatinib<br/>Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) <br/><br/>Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

6 notices published against this procurement.

PublishedTypeRegimeNotice
26 Jun 2024 Contract notice (F02) Earlier regulations 019556-2024
26 Jun 2024 Tender (tender) · 1ed04a4a-f1d8-40b9-abc7-76858de93880-762326
3 Jul 2024 Tender (tender) · 2304fa59-73d8-47d1-952d-0d04d869b0c9-764064
23 Jul 2024 Tender (tender) · 47ef1a65-cb67-4ea3-b4a6-97ac53d30ebf-769893
17 Oct 2024 Contract award notice (F03) Earlier regulations 033646-2024
17 Oct 2024 Award (award) · 5ce17d64-f30a-47b5-916f-e45e3f31e0da-795000

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.